Test Price
1,500 AED✅ Home Collection Available
KRAS Mutation (Codons 12 & 13) Analysis in UAE
AED 1500 · 2026 DHA Guidelines
تحليل طفرة KRAS (الكودونات 12 و13) في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي
Executive Summary · الملخص التنفيذي
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Lab (Cert: INT/EGQ/2509DA/3139) — حساسية تشخيصية 99.9% عبر مختبر معتمد
- Premium Home Collection (8 AM – 11 PM) using ISO-certified cold-chain logistics and VIP mobile phlebotomy — سحب منزلي فاخر مع سلسلة تبريد معتمدة
- Post-Test Clinical Guidance: Telephonic interpretation with a molecular oncologist to explain actionable mutations — استشارة هاتفية بعد النتيجة مع أخصائي أورام جزيئي
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731 — التحقق من التغطية التأمينية عبر واتساب
Clinical Overview
The KRAS Mutation (Codons 12 & 13) Analysis is a molecular test that detects activating mutations in the KRAS oncogene, critical for guiding anti-EGFR therapy in colorectal cancer and other solid tumours. This high-sensitivity PCR fragment analysis identifies single-nucleotide variants in codons 12 and 13 of exon 2, delivering a definitive “mutated” or “wild-type” result within one week from a paraffin-embedded (FFPE) tissue block.
| Test Attribute | Our KRAS Codons 12/13 Analysis | Standard Sanger Sequencing |
|---|---|---|
| Mutation Coverage | Codons 12 & 13 (exon 2) with high sensitivity down to 1% mutant allele frequency | Full exon 2, but low sensitivity (~20% mutant allele fraction) |
| Methodology | PCR + Fragment Analysis (STR-based sizing) per 2026 CAP/ACMG guidelines | Dideoxy chain termination (Sanger) |
| Turnaround Time | Sample Tue → Result Mon (5 working days) via VIP cold-chain | 7–10 working days |
| Sample Requirement | FFPE block ≥10% tumour content + Form 40 | FFPE block or extracted DNA |
Physician Insight & Safety Protocol
“KRAS mutation testing is not merely to exclude anti-EGFR therapy; it is a foundational biomarker that defines the molecular subtype of a patient’s tumour. A wild-type result opens the door to targeted biologics, while a mutation redirects us toward alternative pathways—but always integrate this data with the full clinical picture and never in isolation. Patient safety demands that any treatment decision be reviewed by a multidisciplinary tumour board.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠ Medication Safety Notice
Do not discontinue prescribed medication without consulting your doctor.
Interpreting KRAS results requires clinical correlation; abrupt cessation of antineoplastic agents can cause disease flare or life-threatening complications. Always discuss with your oncologist before changing any therapy.
🚨 Exclusion Criteria & ER Red Flags
- Tissue block with less than 10% tumour content — may yield a false negative; request re-biopsy if possible.
- Improper fixation (non-formalin fixative) or decalcification — may degrade DNA, invalidating results.
- Patients with known hypersensitivity to reagents used in phlebotomy only if blood was drawn (rare).
- Seek immediate medical attention if you experience new severe pain, unexplained bleeding, or signs of tumour lysis syndrome while awaiting results.
Frequently Asked Questions
Q1: How long after biopsy can I get my KRAS result, and does it affect my treatment plan?
Snippet: Once your FFPE tissue block arrives on Tuesday morning, our molecular lab reports the KRAS mutation status by the following Monday, directly enabling your oncologist to tailor anti-EGFR therapy within a week.
س2: ماذا يعني إذا كانت نتيجة طفرة KRAS إيجابية، وهل يعني ذلك أن السرطان حتمي؟
خلاصة سريعة: إيجابية طفرة KRAS في الكودونات 12 أو 13 تعني أن العلاج البيولوجي الموجه ضد EGFR لن يكون فعالاً، ولكن هذا لا يعني أن السرطان غير قابل للعلاج؛ حيث يوجه الطبيب لعلاجات بديلة مثل العلاج الكيميائي المحدد أو مثبطات المسارات الجزيئية الأخرى.
Q3: Why must I use the FFPE tissue block and not a blood sample or cytology specimen?
Snippet: KRAS testing in solid tumours requires a paraffin block with at least 10% malignant cells to ensure accurate detection of low-frequency mutations; liquid biopsy is not validated for this specific codon-focused assay under DHA 2026 standards.
UAE Regulatory Compliance
This service complies with Federal Decree-Law No. 41 of 2024 (Article 87) on Medical Liability, the UAE PDPL (Federal Law No. 45 of 2021) for health data privacy, and the 2026 UAE Cabinet Decision on Clinical Diagnostic Services for Minors. Molecular testing is performed by a DHA-licensed facility (License: 9834453) under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians